Equities Analysts Offer Predictions for AstraZeneca plc’s FY2022 Earnings (AZN)

AstraZeneca plc (NYSE:AZN) – Stock analysts at Leerink Swann issued their FY2022 earnings estimates for AstraZeneca in a research report issued on Thursday, according to Zacks Investment Research. Leerink Swann analyst S. Fernandez forecasts that the company will post earnings of $3.15 per share for the year. Leerink Swann has a “Market Perform” rating and a $38.00 price target on the stock.

AZN has been the subject of several other reports. JPMorgan Chase & Co. raised shares of AstraZeneca from a “neutral” rating to an “overweight” rating in a research note on Friday, December 29th. Zacks Investment Research cut shares of AstraZeneca from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. BMO Capital Markets set a $38.00 price target on shares of AstraZeneca and gave the stock a “buy” rating in a research note on Wednesday, January 10th. Credit Suisse Group raised shares of AstraZeneca from a “neutral” rating to an “outperform” rating in a research note on Monday, October 16th. Finally, ValuEngine raised shares of AstraZeneca from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 3rd. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $35.20.

Shares of AstraZeneca (AZN) traded down $0.49 during mid-day trading on Friday, reaching $33.61. 8,803,388 shares of the company’s stock traded hands, compared to its average volume of 4,510,000. The company has a quick ratio of 0.72, a current ratio of 0.80 and a debt-to-equity ratio of 0.93. The firm has a market cap of $83,560.00, a P/E ratio of 28.48, a P/E/G ratio of 2.03 and a beta of 0.74. AstraZeneca has a 52-week low of $28.43 and a 52-week high of $36.70.

AstraZeneca (NYSE:AZN) last announced its earnings results on Friday, February 2nd. The company reported $1.30 EPS for the quarter, topping the consensus estimate of $0.44 by $0.86. The firm had revenue of $5.78 billion for the quarter, compared to the consensus estimate of $5.49 billion. AstraZeneca had a net margin of 13.36% and a return on equity of 34.74%. The business’s quarterly revenue was up 3.4% on a year-over-year basis. During the same period last year, the company posted $1.21 EPS.

Several large investors have recently added to or reduced their stakes in the stock. First Republic Investment Management Inc. grew its stake in shares of AstraZeneca by 14.1% in the fourth quarter. First Republic Investment Management Inc. now owns 55,825 shares of the company’s stock valued at $1,938,000 after buying an additional 6,909 shares in the last quarter. FDx Advisors Inc. boosted its position in AstraZeneca by 8.8% during the fourth quarter. FDx Advisors Inc. now owns 156,322 shares of the company’s stock worth $5,424,000 after purchasing an additional 12,620 shares during the period. Synovus Financial Corp bought a new position in AstraZeneca during the fourth quarter worth $327,000. American International Group Inc. bought a new position in AstraZeneca during the fourth quarter worth $1,976,000. Finally, Arrowstreet Capital Limited Partnership bought a new position in AstraZeneca during the fourth quarter worth $25,455,000. 14.79% of the stock is owned by institutional investors and hedge funds.

The company also recently announced a semiannual dividend, which will be paid on Monday, March 19th. Investors of record on Friday, February 16th will be paid a $0.95 dividend. The ex-dividend date of this dividend is Thursday, February 15th. This represents a dividend yield of 5.62%. AstraZeneca’s dividend payout ratio is presently 116.10%.

WARNING: “Equities Analysts Offer Predictions for AstraZeneca plc’s FY2022 Earnings (AZN)” was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece on another site, it was stolen and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://ledgergazette.com/2018/02/11/astrazeneca-plc-forecasted-to-earn-fy2022-earnings-of-3-15-per-share-azn.html.

About AstraZeneca

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Get a free copy of the Zacks research report on AstraZeneca (AZN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply